

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

Publication number:

0018 136  
A1

(12)

# EUROPEAN PATENT APPLICATION

(21) Application number: 80301053.7

(51) Int. Cl.: C 07 D 473/22, C 07 D 473/20,  
A 61 K 31/52

(22) Date of filing: 02.04.80

(30) Priority: 05.04.79 GB 7912052  
05.06.79 GB 7919505

(71) Applicant: Johann A. Wuelfling, Stresemannallee 6,  
D-4040 Neuss (DE)

(43) Date of publication of application: 29.10.80  
Bulletin 80/22


(72) Inventor: Goring, Joachim Ewald, Sauerweinstrasse 25,  
3212 Gronau (Leine) (DE)

(84) Designated Contracting States: AT BE CH DE FR GB IT  
LI NL SE

(74) Representative: Dawson, Hugh Balforde, Dr. et al,  
European Patent Attorney BEECHAM  
PHARMACEUTICALS Yew Tree Bottom Road, Epsom,  
Surrey KT18 5XQ. (GB)

(54) Xanthine derivatives, a process for their preparation and their use in pharmaceutical compositions.

(57) Compounds of the formula (II):



(II)

wherein:


X is sulphur and Y is oxygen or sulphur;  
R<sub>1</sub> is an alkyl group of up to 6 carbon atoms;  
R<sub>2</sub> is an alkyl group of up to 6 carbon atoms; and  
n is 1; or  
X is oxygen and Y is sulphur;  
one of R<sub>1</sub> and R<sub>2</sub> is an alkyl group of up to 6 carbon atoms  
and the other is an alkyl group of 2 to 6 carbon atoms; and  
n is 1 or 2, having useful pharmacological activity,  
pro-drugs therefor, a process for their preparation, phar-  
maceutical compositions containing said compounds or  
pro-drugs, and intermediate in their preparation of the  
compounds.

EP 0 018 136 A1

0018136

Xanthine Derivatives,  
a Process for their Preparation  
and their use in Pharmaceutical Compositions

British Patent Specification No. 1441562 discloses  
inter alia that compounds such as those of the formula (I):




wherein  $A_1$  and  $A_2$  are alkyl groups and  $A_3$  is an alkylene moiety possess blood flow improving properties. A.K. Armitage et al., British J. Pharmacol., (1961), 17, 202 discloses 7-acetylmethyl-1,3-dimethyl-6-thioxanthine as a bronchodilator and coronary dilator.

It has now been found that a class of compounds yet further removed from naturally occurring xanthines effect an improvement in the metabolic status of ischaemic skeletal muscle by increasing oxygen tension and/or contractility in the tissue. The compounds are thus of potential use as agents for the treatment of peripheral vascular diseases such as intermittent claudication.

The present invention provides the structurally distinct compounds of the formula (II):

- 2 -



wherein:

$X$  is sulphur and  $Y$  is oxygen or sulphur;

$R_1$  is an alkyl group of up to 6 carbon atoms;

$R_2$  is an alkyl group of up to 6 carbon atoms; and  
 5  $n$  is 1; or


$X$  is oxygen and  $Y$  is sulphur;

one of  $R_1$  and  $R_2$  is an alkyl group of up to 6 carbon atoms  
 and the other is an alkyl group of 2 to 6 carbon atoms; and  
 10  $n$  is 1 or 2; or a pro-drug therefor.

10

When used herein the term "pro-drug" means a compound  
 metabolised in vivo to a compound of the formula (I) or  
 its salt. A pro-drug may be identified by administering  
 the pro-drug to a mammal such as a rat, mouse, monkey or  
 15 man and identifying the compound of the formula (I) or its  
 salt, in for example blood or urine.

When  $n$  is 1 or 2, it is preferably 1. Thus, certain  
 particularly suitable compounds of the formula (II) are  
 those of the formula (III):



3 -


wherein  $R_1$ ,  $R_2$ , X and Y are as defined in relation to formula (II); or a pro-drug therefor.

Alkyl groups  $R_1$  and  $R_2$  worthy of mention for the compounds of the formulae (II) and (III) include the methyl  
 5 ethyl, iso-propyl, n-butyl, iso-butyl, n-pentyl and n-hexyl groups.

Favourably in formulae (II) and (III)  $R_1$  and  $R_2$  together contain 3 - 10 carbon atoms and more favourably they together contain 4, 5, 6, 7 or 8 carbon atoms.

10 Aptly Y in the compounds of the formulae (II) and (III) is an oxygen atom and X is a sulphur atom.

Thus certain favoured compounds of this invention include those of the formula (IV), or a pro-drug therefor:



wherein  $R_1$  and  $R_2$  are as defined in formula (II).


15 Alkyl groups  $R_1$  and  $R_2$  worthy of mention and favourable total carbon atom numbers therefor are as to described under formula (III).

A preferred value for  $R_1$  in formula (IV) is the n-butyl group. Ethyl is also of interest.

20 A preferred value for  $R_2$  in formula (IV) is the n-butyl group. Ethyl is also of interest.


- 4 -

From the foregoing it will be appreciated that one compound possessing particularly suitable properties is that of the formula



10 Also aptly Y in the compounds of the formula (II) is a sulphur atom and X is an oxygen atom.

Thus certain other favoured compounds of this invention include those of the formula (V) or a pro-drug therefor




wherein n is as defined in relation to formula (II); and  
 15 one of  $R_1^1$  and  $R_2^1$  is an alkyl group of up to 6 carbon atoms and the other is an alkyl group of 2 to 6 carbon atoms.

Suitable groups  $R_1^1$  and  $R_2^1$  include ethyl, iso-propyl, n-butyl, isobutyl, n-pentyl and n-butyl.

Favourably  $R_1^1$  and  $R_2^1$  together contain 4-10 carbon  
 20 atoms, more favourably 4, 5, 6, 7 or 8 carbon atoms.

Preferably  $R_1$  is butyl and  $R_2$  is ethyl.

Other compounds of this invention are of the formula (VI), or a pro-drug therefor:



wherein  $R_1$  and  $R_2$  are as defined in relation to formula (II).

Alkyl groups  $R_1$  and  $R_2$  worthy of mention and favourable total carbon atom numbers therefor are as so described under formula (III).

Preferably  $R_1$  and  $R_2$  are both n-butyl.

Compounds of the formula (II) have useful pharmacological activity, as disclosed hereinbefore, in effecting an improvement in the metabolic status of ischaemic skeletal muscle, by increasing oxygen tension or contractility in the tissue.

Individual compounds of the formula (II) have one or both of these activities. The individual activity profile may be readily ascertained by the two routine pharmacological tests disclosed hereinafter. Nevertheless examples of compounds of interest for each or both activities are given here:

Examples of compounds of the formula (II) which are of particular interest for their activity in increasing ischaemic skeletal muscle contractility are those of the formulae (IV) and (V).

Examples of compounds of the formula (II) which are of particular interest for their activity in increasing oxygen tension in ischaemic skeletal muscle are those of the

- 6 -

formula (VI), in particular 1,3-di-n-butyl-7-(2-oxopropyl)-2,6-thioxanthine.

5        Examples of compounds of the formula (II) which are of particular interest for both of the foregoing activities are those of the formulae (IV) and (V) having the preferred variable values so described under the relevant formula.

As mentioned hereinbefore the compounds of the formula (II), which have either or both of these activities are of potential use for the treatment of peripheral vascular diseases, such as intermittent claudication.

The present invention therefore also provides a pharmaceutical composition which comprises a compound of the formula (II) or a pro-drug therefor and a pharmaceutically acceptable carrier.

The composition of this invention will normally be provided in the form of a discrete unit dose such as a tablet, capsule or defined quantity of the composition in a form suitable for dissolution to provide an injectable solution. Particularly suitable forms of such compositions are those adapted for oral administration such as tablets or capsules.

Unit dose compositions of this invention may contain 1 to 500 mgs of active agent. Compounds of this invention wherein the 7-position side chain is other than 2-oxopropyl or a group convertible thereto will normally be present in such compositions in a dose from 100 to 500 mgs, for example 200 to 400 mgs. Compounds of this invention wherein the 7-position side chain is 2-oxopropyl or a group convertible thereto will normally be present in such compositions in a dose of from 1 to 100 mgs, more usually 2.5 to 50 mgs for example 5 to 25 mgs. The unit dose composition will normally be taken from 1 to 4 times daily so that the normal dose for a 70 kg adult human will be




- 7 -

from about 100 to 2000 mgs for a composition containing a compound in which the 7-position substituent is other than 2-oxopropyl or a group convertible thereto and from about 4 to 100 mgs for a composition containing a compound in which the 7-position substituent is a 2-oxopropyl group or a group convertible thereto.

The compositions of this invention may be formulated in conventional manner. Thus oral dosage units may contain such conventional agents as fillers (diluent), lubricants, binders, disintegrants, colourants, flavourings, surface active agents, preservatives, buffering agents, and the like. Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate and the like. Suitable lubricants include stearic acid, magnesium stearate, magnesium lauryl sulphate and the like. Injectable compositions may consist essentially of a sterile, pyrogen free compound of this invention sealed into a vial optionally together with suspending and preserving agents. Such compositions may be made up for administration with sterile water or saline.

The compositions may be prepared by conventional methods of blending, filling, tableting or the like.

The present invention also provides a process for the preparation of the compounds of this invention which process comprises the reaction of a salt of a compound of the formula (VII):



wherein  $R_1$ ,  $R_2$ , X and Y are as defined in relation to

formula (II) with a compound of the formula (VIII):



wherein n and m are as defined in relation to formula (II) or a chemical equivalent thereof.

5      Suitable chemical equivalents of the chloro-compound of the formula (VIII) include the corresponding bromo- and iodo-compounds and analogous active esters such as mesylates or tosylates.

10      The salt of the compound of the formula (VII) will normally be an alkali metal salt such as the sodium or potassium salt and may be preformed or generated in situ by the presence of a base such as an hydroxide or ethanolate.

Suitable solvents for use in such processes include lower alkanols such as methanol, ethanol or the like.

15      The reaction is generally carried out at an ambient or elevated temperature, for example from 20° to 80°C. It is often convenient to carry out the reaction in a solvent under reflux.

20      When the desired compound has been produced it may be recovered by distilling off the solvent, by precipitation with a miscible non-solvent or the like.

Purification of the compound of this invention may be carried out by conventional methods such as crystallisation, recrystallisation and chromatography.


25      Compounds of the formula (II) wherein n is 2 may be prepared by the reaction of a compound of the formula (VII) with methyl vinyl ketone or 2-chlorobutan-3-one. This reaction may be carried out under conditions as described herein for reaction with a compound of the formula (VIII).

- 9 -

Certain compounds of the formula (VII) are novel and form part of this invention. Thus the present invention provides the compound of the formula (VII) as hereinbefore described wherein  $R_1$  and  $R_2$  are each n-butyl groups, X is sulphur and O is oxygen or sulphur and salts thereof.

Compounds of the formula (VII) wherein Y is a sulphur atom and X is an oxygen atom may be prepared by the process of K.R.H. Wooldrige and R. Slack, J. Chem. Soc., 1962, 1863-68.

The compounds of the formula (VII) wherein X is a sulphur atom and Y is an oxygen atom may be prepared by the reaction of a compound of the formula (IX):



wherein  $R_1$  and  $R_2$  are as defined in relation to formula (II) with sodium carbonate, formamide, formic acid and sodium dithionite. This reaction is generally begun at a depressed temperature such as 3 - 5°C and gradually warmed until completion occurs at an elevated temperature such as 160 - 190°C.

The compounds of formula (IX) may be prepared according to the procedures of Bredeneck et al., Chem. Ber., 88, 1306-1312 (1955). Their conversion into compounds of the formula (VIII) as described above may be viewed in the light of Papesch et al., U.S. Patent No. 2615020.

Compounds of the formula (VII) wherein X and Y are both sulphur atoms may be prepared by the reaction of  $P_4S_{10}$  and a compound of the formula (VIII) wherein one of X and Y is a sulphur atom and the other is an oxygen atom

- 10 -

or both of X and Y are oxygen atoms; see for example U.S. patent specification no. 3135753, Chem. Zentralblatt 37-2695 (1966), Chem. Zentralblatt 27-1557 (1966) and Chem. Zentralblatt 40-0983 (1968).

5           The invention also provides a method for the treatment or prophylaxis of peripheral vascular disease, which method comprises the administration to the sufferer of a therapeutically effective amount of a compound of the formula (II) or a pro-drug therefor.

10           The following Examples illustrate the invention.

- 11 -

Example 11-n-Butyl-3-ethyl-7-(2-oxopropyl)-6-thioxanthine (1)

1-n-Butyl-3-ethyl-6-thioxanthine (4 g) was dissolved in dimethyl formamide (30 ml) and a small amount of potassium carbonate was added. To this mixture, 1-bromopropan-2-one (2,7 g) was added dropwise at room temperature, with stirring. The reaction was heated at about 50°C for two hours. The reaction mixture was then extracted with chloroform several times, the chloroform phase washed with 1N KOH and water, dried with sodium sulphate, filtered and the chloroform removed in vacuo to yield a red/brown oil which, on crystallisation in a mixture of ethylacetate/petroleum, gave 1-n-butyl-3-ethyl-7-(2-oxopropyl)-6-thioxanthine as a white powder.

Melting point: 173 - 174°C

Yield: 1 g.

## Elemental Analysis

	Calculated	Found
C	54,55	55,14
H	6,49	6,34
N	18,19	17,89
O	10,39	10,60
S	10,39	10,01

Example 21,3-Di-n-butyl-7-(3-oxobutyl)-6-thioxanthine (2)

1,3-di-n-butyl-6-thioxanthine (8,3 g), methylvinylketone (2,9 ml) and triethylamine (1 ml) were dissolved in ethanol (10 ml) and the mixture was slowly heated with stirring at 40 - 50°C for one hour. After cooling of the clear  
5 solution, the 1,3-di-n-butyl-7-(3-oxobutyl)-6-thioxanthine precipitated in the form of yellow needles.

Melting point: 118 - 119°C

Yield: 8,5 g

Elemental Analysis

	Calculated	Found
C	58,29	58,28
H	7,43	7,40
N	16,00	16,12
O	9,14	9,27
S	9,14	8,90

The structure was confirmed by NMR spectroscopy.

Using an analogous process the following were prepared:

1-n-butyl-3-ethyl-7-(3-oxobutyl)-6-thioxanthine (3),  
m.pt. 127°C, was prepared in 75% yield. The crystallisation  
solvent was ethanol.

Elemental Analysis					
	C %	H %	N %	O %	S %
Calculated	55,90	6,83	17,39	9,94	9,94
Found	56,08	6,91	16,91	10,23	9,87
	55,95	6,92	17,03	10,35	9,85

- 5 1,3-dimethyl-7-(3-oxobutyl)-6-thioxanthine (4), m.pt. 164°C,  
was prepared in 77% yield. The crystallisation solvent  
was ethyl acetate/methanol.

Elemental Analysis					
	C %	H %	N %	O %	S %
Calculated	49,62	5,26	21,05	12,03	12,03
Found	49,54	5,36	21,29	11,96	11,93
	49,46	5,37	21,26	11,96	11,84

Example 31,3-Di-n-butyl-2-thioxanthine (5)

Sodium carbonate (8 g) was dissolved in formamide (200 ml) and 1,3-di-n-butyl-2-thio-4-aminouracil (32 g) was added at a temperature of 3°C with stirring. The mixture was cooled over a period of 1 hour and at a temperature of 3-5°C. Formic acid (16 ml) was added dropwise. The reaction mixture was allowed to stand overnight in a refrigerator. The mixture was then heated to 100°C and then sodium dithionite (5 g) was added at this temperature. To complete the reaction, the mixture was heated to 190°C for 1 hour. After cooling to room temperature with stirring, the oil solidified with crystallisation. The crude product was filtered with suction. To remove coloured by-products, the crude product was dissolved in dilute sodium hydroxide, the solution treated with charcoal and precipitated with acetic acid and the compound was recrystallised from methanol/water to give 1,3-di-n-butyl-2-thioxanthine as white powder.

Melting point: 137°C

Yield: 27,2 g

Elemental Analysis

	Calculated	Found
C	55,69	55,76
H	7,19	7,16
N	19,98	19,90
O	5,77	5,82
S	11,43	11,44



Example 41,3-Di-n-butyl-7-(2-oxopropyl)-2-thioxanthine (6)

1,3-Di-n-butyl-2-thioxanthine (12,6 g) was treated with sodium (1,05 g) in absolute ethanol (45 ml) to give the 1,3-di-n-butyl-2-thioxanthine sodium salt by heating under reflux for one hour. 1-Bromo-propan-n-2-one ( ml) was then added dropwise and the reaction mixture was heated under reflux for a further hour. After cooling to room temperature, the precipitated sodium bromide was filtered off and the solution was evaporated to dryness. The residue was dissolved in chloroform and treated with dilute NaOH to remove unreacted starting material. The chloroform phase was washed with water, dried, filtered and evaporated in vacuo to dryness. This residue was dissolved in methanol and treated with charcoal to remove the colour of the solution. After standing, the 1,3-di-n-butyl-7-(2-oxopropyl)-2-thioxanthine precipitated as a white powder.

Melting point: 131 - 132°C

Yield: 3,5 g

Elemental Analysis

	Calculated	Found
C	57,12	57,16
H	7,19	7,24
N	16,65	16,80
O	9,51	9,40
S	9,53	9,56

Example 51,3-Di-n-butyl-7-(2-oxopropyl)-6-thioxanthine (7)

1,3-Di-n-butyl-6-thioxanthine (5,6 g) was treated with sodium (0,46 g) in absolute ethanol (20 ml) to give the 1,3-di-n-butyl-6-thioxanthine sodium salt by heating under reflux for one hour. 1-chloropropan-2-one (2,31 g) dissolved in ethanol (20 ml) was added dropwise and the reaction mixture heated under reflux for a further 5 hours. The reaction was then complete (as judged by TLC). After standing overnight, the precipitated sodium chloride was filtered off under suction. The dark filtrate was extracted with chloroform. The chloroform phase was washed three times with 1N NaOH, washed with water, dried with sodium sulphate, filtered and the chloroform was removed in vacuo to yield a dark brown residue. On crystallisation from ethanol the residue gave 1,3-di-n-butyl-7-(2-oxo-propyl)-6-thioxanthine as a white powder.

Melting point: 152°C

Yield: 0,6 g

Elemental analysis:

	Calculated	Found
C	57,11	57,29
H	7,19	7,02
N	16,65	16,73
O	9,50	9,61
S	9,55	9,50

The structure was confirmed by NMR spectroscopy.

Using an analogous process the following two compounds were prepared:

1,3-Di-n-butyl-7-(2-oxopropyl)-2,6-di-thioxanthine (8)

Melting point: 173°C

Yield: 1,2 g

crystallisation solvent: ethanol

Elemental analysis:

	Calculated	Found
C	54,52	54,64
H	6,86	6,81
N	15,89	15,93
O	4,54	4,74
S	18,19	17,87

The structure was confirmed by NMR spectroscopy.

1,3-Di-ethyl-7-(2-oxopropyl)-2-thioxanthine (9)

Melting point: 202°C

Yield: 7,9 g  $\hat{=}$  41,9% of the theory

crystallisation solvent: ethanol

Elemental analysis:

	Calculated	Found
C	51,41	51,18
H	5,75	6,02
N	19,98	19,95
O	11,41	11,44
S	11,44	11,36

The structure was confirmed by NMR spectroscopy.

Example 12Composition

1,3-Di-n-butyl-7-(2-oxopropyl)-2-thioxanthine, magnesium stearate and microcrystalline cellulose may be blended together and passed through a 40 mesh sieve (UK). The resulting mixture may be tabletted on a conventional rotary machine to produce a batch of 5000 tablets of the following composition:

1,3-Di-n-butyl-7-(2-oxopropyl)-	
2-thioxanthine	10 mg
magnesium stearate	0.2 mg
microcrystalline cellulose	189.8 mg

PharmacologyMethodology

Cats of either sex were anaesthetized by i.p. injection of urethane/chloralose (120/60 mg/kg). The intraduodenal (i.d.) administration of compounds was conducted by means of a plastic catheter which was inserted  
5 into the duodenum following midline incision at the abdominal cavity.

i) pO<sub>2</sub>-measurements

Measurement of muscle surface pO<sub>2</sub>. The skin above the measuring site (3-4 mm in diameter) was removed and one  
10 multiwire-surface electrode (Eschweiler, Kiel) was placed on the gastrocnemius muscle of each hindlimb. The femoral artery in one hindlimb was ligated in order to induce ischaemia. Muscle temperature was controlled by means of a thermocouple (Ellab, Copenhagen). The electrode current  
15 was measured every 6 to 8 s and collected for periods of 4 min (Hewlett-Packard programmable data logger system 3051 A). After each period, mean value and standard deviation was calculated.

ii) Skeletal muscle contractility

20 After dissection of the skin of the calf muscles, the sciatic nerve was cut about 3 cm proximal to the knee. The tendon of the calf muscles was cut and connected with an isometric force transducer (SWEMA, SG 3). In order to maintain constant differences and a resting  
25 tension of 100 p in cats and 25 p in rats, the hindlimb was fixed at the tibia by means of a clamp. Direct stimulation of the muscles consisted of square wave pulses of 4 msec duration at a frequency of 2 Hz and at a voltage 50 V in cats. In order to keep the muscles

0018136

- 20 -

wet and at a normal temperature, the muscles were continuously superfused with 0.9% w/v NaCl solution (38°C). Femoral blood flow was restricted by a graded occlusion of the artery leading to a reduction of contractility by ca. 30 %. After having reached a constant level of the contraction force, the appropriate vehicle (NaCl or Methocel) was injected, followed by the test substance.

Resultsi) pO<sub>2</sub>-measurements

Compound	dosage (mg/kg) i.d.*	n	hypoxic tissue			normoxic tissue		
			C <sub>s</sub>	$\overline{\Delta pO_2}$	E	C <sub>s</sub>	$\overline{\Delta pO_2}$	E
1	12.5	2	1	1.4	1.4	1	12.9	12.9
3	12.5	3	0.67	3.8	2.7	1	7.0	7.0
	32.0	3	0.67	4.5	3.0	1	2.0	2.0
6	0.1	4	1	6.2	6.2	0.67	8.4	5.7
	0.3	4	1	5.3	5.3	1	5.7	5.7
8	2.0	4	0.75	6.6	5.0	0.5	9.9	4.9

ii) skeletal muscle contractility

Compound	dosage (mg/kg) i.d.*	n	average increase (%) <sup>o</sup>
1	2.0	2	+22.2
	5.0	2	+12.1
3	12.5	2	+10.4
4	12.5	1	+7.1
	32.0	3	+21.1

Compound	(mg/kg) i.d.*	n	increase (%) <sup>p</sup>
6	0.3	2	+ 5.3
	0.8	3	+ 7.5
	2.0	4	+10.3
	5.0	3	+17.1
9	32.0	2	+ 9.4

n = number of animals

C<sub>s</sub> = significance coefficient = number of measuring sites with significant pO<sub>2</sub> increase per total number of measuring sites

Δ pO<sub>2</sub> = mean pO<sub>2</sub> increase in experiments with significant pO<sub>2</sub> increase (Torr)



$E = \text{efficiency - index} = C_s \times \overline{\Delta pO_2} \text{ (Torr)}$

Control values : E between 0 and 1.4 Torr

\* i.d. = intraduodenal application of a suspension in  
Methocel (methyl cellulose)


(%)<sup>0</sup> of initial values

#### Toxicity

No toxic effects were observed at the test dosages.

Claims


1. A compound of the formula (II):



characterised in that


- X is sulphur and Y is oxygen or sulphur;  
 R<sub>1</sub> is an alkyl group of up to 6 carbon atoms;  
 5 R<sub>2</sub> is an alkyl group of up to 6 carbon atoms; and  
 n is 1; or  
 X is oxygen and Y is sulphur;  
 one of R<sub>1</sub> and R<sub>2</sub> is an alkyl group of up to 6 carbon atoms and  
 the other is an alkyl group of 2 to 6 carbon atoms; and  
 10 n is 1 or 2; or a pro-drug therefor.

2. A compound according to claim 1 of the formula (III):



characterised in that R<sub>1</sub>, R<sub>2</sub>, X and Y are as defined in claim 1; or a pro-drug therefor.


3. A compound according to claim 1 of the formula (IV):



characterised in that  $R_1$  and  $R_2$  are as defined in claim 1; or a pro-drug therefor.

4. 1,2-Di-n-butyl-7-(2-oxopropyl)-2-thioxanthine.


5. A compound according to claim 1 of the formula (V) or a pro-drug therefor:



characterised in that  $n$  is as defined in claim 1, and one of  $R_1$  and  $R_2$  is an alkyl group of up to 6 carbon atoms and the other is an alkyl group of 2 to 6 carbon atoms.

6. 1-n-Butyl-3-ethyl-7-(2-oxopropyl)-6-thioxanthine or  
10 1-n-butyl-3-ethyl-7-(3-oxobutyl)-6-thioxanthine.

7. A compound according to claim 1 of the formula (VI) or a pro-drug therefor:




characterised in that  $R_1$  and  $R_2$  are as defined in claim 1.


8. 1,3-Di-n-butyl-7-(2-oxopropyl)-2,6-dithioxanthine.

15 9. A pharmaceutical composition, which composition comprises a compound according to claim 1 together with a pharmaceutically acceptable carrier.

10. A process for the preparation of a compound according to claim 1, characterised by the reaction of a salt of compound of the formula (VII):



5 wherein  $R_1$ ,  $R_2$ , X and Y are as defined in claim 1 with a compound of the formula (VIII):




wherein n is as defined in claim 2 or a chemical equivalent thereof, or, when n is 2 in the compound of the formula (II), with methyl vinyl ketone.

10 11. 1,3-Di-n-butyl-2-thioxanthine or 1,3-Di-n-butyl-2,6-dithioxanthine.

Claims

1. A process for the preparation of a compound of the formula (II):



wherein:

X is sulphur and Y is oxygen or sulphur;


5  $R_1$  is an alkyl group of up to 6 carbon atoms;

$R_2$  is an alkyl group of up to 6 carbon atoms; and  
n is 1; or


X is oxygen and Y is sulphur;

one of  $R_1$  and  $R_2$  is an alkyl group of up to 6 carbon atoms  
10 and the other is an alkyl group of 2 to 6 carbon atoms; and  
n is 1 or 2;

characterised by the reaction of a salt of a compound of the formula (VII):



15 wherein  $R_1$ ,  $R_2$ , X and Y are as defined above with a compound of the formula (VIII):



wherein n is as defined above or a chemical equivalent thereof, or, when n is 2 in the compound of the formula (II), with methyl vinyl ketone.

2. A process according to claim 1, characterised in that n is 1.
3. A process according to claim 2, characterised in that X is S and Y is O.
- 5 4. A process according to claims 2 and 3, characterised in that  $R_1$  and  $R_2$  are each n-butyl.
5. A process according to claim 1, characterised in that X is O and Y is S.
- 10 6. A process according to claim 5, characterised in that  $R_1$  is n-butyl and  $R_2$  is ethyl.
7. A process according to claim 1, characterised in that X and Y are both S.
8. A process according to claim 7, characterised in that  $R_1$  and  $R_2$  are each n-butyl.
- 15 9. A process for the preparation of 1,3-di-n-butyl-2-thioxanthine, characterised by the reaction of 4-amino-1,3-di-n-butyl-2-thiouracil with sodium carbonate, formamide, formic acid and sodium dithionite.
- 20 10. A process for the preparation of 1,3-di-n-butyl-2,6-dithioxanthine, characterised by the reaction of  $P_4S_{10}$  and 1,3-di-n-butyl-2-thioxanthine or 1,3-di-n-butyl-6-thioxanthine.

## EUROPEAN SEARCH REPORT

Application number

EP 80 30 1053.7

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	<p>Chemical Abstracts vol. 57, no. 5, 3 September 1962 Columbus, Ohio, USA K.R.H. WOOLDRIDGE et al. "The synthesis of some 6-thioxanthines" column 5924 to 5926 * column 5925 h *</p> <p>&amp; J. Chem Soc., 1962, pages 1863 to 1868</p> <p>FR - A - 1 167 425 (J.R. GEIGY) * formula III *</p> <p>DE - A1 - 2 330 742 (CHEMISCHE WERKE ALBERT) * claim 2 *</p>	<p>1,2,5</p> <p>1-3</p> <p>10</p>	<p>C 07 D 473/22 C 07 D 473/20 A 61 K 31/52</p> <p>TECHNICAL FIELDS SEARCHED (Int. Cl.)</p> <p>A 61 K 31/52 C 07 D 473/00</p> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons</p>
A	<p>Chemical Abstracts vol. 85, no. 21, 22 November 1976 Columbus, Ohio, USA B. KOKEL et al. "A process for pre- paring <math>\alpha</math>-ketols from diazomethyl ketones" page 487, column 2, abstract no. 159334p</p> <p>&amp; C.R. Hebd. Seances Acad. Sci., Ser. C, vol. 282, no. 24, 1976, pages 1125 to 1127 (Fr)</p>		<p>&amp;: member of the same patent family, corresponding document</p>
<p><input checked="" type="checkbox"/> The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
Berlin	15-07-1980	FROELICH	

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 018 136**  
**B1**

*Handwritten signature and initials*

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **16.11.83**

(21) Application number: **80301053.7**

(22) Date of filing: **02.04.80**

(51) Int. Cl.<sup>3</sup>: **C 07 D 473/22,**  
**C 07 D 473/20,**  
**A 61 K 31/52**

(54) **Xanthine derivatives, a process for their preparation and their use in pharmaceutical compositions.**

(30) Priority: **05.04.79 GB 7912052**  
**05.06.79 GB 7919505**

(43) Date of publication of application:  
**29.10.80 Bulletin 80/22**

(45) Publication of the grant of the patent:  
**16.11.83 Bulletin 83/46**

(84) Designated Contracting States:  
**BE CH DE FR GB IT LI NL SE**

(56) References cited:  
**DE - A - 2 330 742**  
**FR - A - 1 167 425**

**Chemical Abstracts vol. 57, no. 5, 3 September**  
**1962 Columbus, Ohio, USA K.R.H.**  
**WOOLDRIDGE et al. "The synthesis of some 6-**  
**thioxanthines" column 5924 to 5926**

**Chemical Abstracts vol. 85, no. 21, 22**  
**November 1976 Columbus, Ohio, USA B. KOKEL**  
**et al. "A process for preparing alpha-ketols from**  
**diazomethyl ketones" page 487, column 2,**  
**abstract no. 159334p**

(73) Proprietor: **BEECHAM - WUELFING GmbH & Co.**  
**KG**  
**Stresemannallee 6 P.O. Box 25**  
**D-4040 Neuss (DE)**

(72) Inventor: **Goring, Joachim Ewald**  
**Sauerweinstrasse 25**  
**3212 Gronau (Leine) (DE)**

(74) Representative: **Russell, Brian John et al,**  
**European Patent Attorney Beecham**  
**Pharmaceuticals Great Burgh Yew Tree Bottom**  
**Road**  
**Epsom Surrey, KT18 5XQ (GB)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.


**EP 0 018 136 B1**



# 0018 136

Xanthine derivatives, a process for their preparation and their use  
in pharmaceutical compositions

GB—A—1441562 discloses inter alia that compounds such as those of the formula (I):




wherein A<sub>1</sub> and A<sub>2</sub> are alkyl groups and A<sub>3</sub> is an alkylene moiety possess blood flow improving properties. J. Chem. Soc., 1962, 1863 to 1868 discloses 7-acetylmethyl-1,3-dimethyl-6-thioxanthine and 7-acetylmethyl-3-isobutyl-1-methyl-6-thioxanthine as coronaro- and broncho-dilators.

15 FR—A—1,167,425 generically discloses certain 2-thioxanthines only as intermediates.

It has now been found that a class of compounds yet further removed from naturally occurring xanthines effect an improvement in the metabolic status of ischaemic skeletal muscle by increasing oxygen tension and/or contractility in the tissue. The compounds are thus of potential use as agents for the treatment of peripheral vascular diseases such as intermittment claudication.

20 The present invention provides the structurally distinct compounds of the formula (II):




wherein:

X is a sulphur and Y is oxygen or sulphur;  
R<sub>1</sub> is an alkyl group of up to 6 carbon atoms;  
R<sub>2</sub> is an alkyl group of up to 6 carbon atoms; and  
35 n is 1; or

X is oxygen and Y is sulphur;  
one of R<sub>1</sub> and R<sub>2</sub> is an alkyl group of up to 6 carbon atoms and the other is an alkyl group of 2 to 3 carbon atoms; and  
n is 1 or 2;

40 When n is 1 or 2, it is preferably 1. Thus, certain particularly suitable compounds of the formula (II) are those of the formula (III):



wherein R<sub>1</sub>, R<sub>2</sub>, X and Y are as defined in relation to formula (II);

Alkyl groups R<sub>1</sub> and R<sub>2</sub> worthy of mention for the compounds of the formulae (II) and (III) include the methyl ethyl, iso-propyl, n-butyl, iso-butyl, n-pentyl and n-hexyl groups.


55 Favourably in formulae (II) and (III) R<sub>1</sub> and R<sub>2</sub> together contain 3—10 carbon atoms and more favourably they together contain 4, 5, 6, 7 or 8 carbon atoms.

Aply Y in the compounds of the formulae (II) and (III) is an oxygen atom and X is a sulphur atom.

60

# 0018 136

Thus certain favoured compounds of this invention include those of the formula (IV),




10 wherein  $R_1$  and  $R_2$  are as defined in formula (II).

Alkyl groups  $R_1$  and  $R_2$  worthy of mention and favourable total carbon atom numbers thereof are as to described under formula (III).


A preferred value for  $R_1$  in formula (IV) is the n-butyl group. Ethyl is also of interest.

15 A preferred value for  $R_2$  in formula (IV) is the n-butyl group. Ethyl is also of interest.

From the foregoing it will be appreciated that one compound possessing particularly suitable properties is that of the formula



Also aptly Y in the compounds of the formula (II) is a sulphur atom and X is an oxygen atom.  
Thus certain other favoured compounds of this invention include those of the formula (V)




40 wherein n is as defined in relation to formula (II); and one of  $R_1^1$  and  $R_2^1$  is an alkyl group of up to 6 carbon atoms and the other is an alkyl group of 2 or 3 carbon atoms.

Suitable groups  $R_1^1$  and  $R_2^1$  as appropriate include ethyl, iso-propyl, n-butyl, isobutyl, n-pentyl and n-hexyl.

45 Favourably  $R_1^1$  and  $R_2^1$  together contain 4, 5, 6, 7 or 8 carbon atoms.

Preferably  $R_1$  is butyl and  $R_2$  is ethyl.

Other compounds of this invention are of the formula (VI),



wherein  $R_1$  and  $R_2$  are as defined in relation to formula (II).

60 Alkyl groups  $R_1$  and  $R_2$  worthy of mention and favourable total carbon atom numbers therefor are as so described under formula (III).

Preferably  $R_1$  and  $R_2$  are both n-butyl.

Compounds of the formula (II) have useful pharmacological activity, as disclosed hereinbefore, in effecting an improvement in the metabolic status of ischaemic skeletal muscle, by increasing oxygen tension or contractility in the tissue.

65 Individual compounds of the formula (II) have one or both of these activities. The individual

activity profile may be readily ascertained by the two routine pharmacological tests disclosed hereinafter. Nevertheless examples of compounds of interest for each or both activities are given here:

Examples of compounds of the formula (II) which are of particular interest for their activity in increasing ischaemic skeletal muscle contractility are those of the formulae (IV) and (V).

5 Examples of compounds of the formula (II) which are of particular interest for their activity in increasing oxygen tension in ischaemic skeletal muscle are those of the formula (VI), in particular 1,3-di-n-butyl-7-(2-oxopropyl)-2,6-thioxanthine.

10 Examples of the compounds of the formula (II) which are of particular interest for both of the foregoing activities are those of the formulae (IV) and (V) having the preferred variable values so described under the relevant formula.

As mentioned hereinbefore the compounds of the formula (II), which have either or both of these activities are of potential use for the treatment of peripheral vascular diseases, such as intermittent claudication.

15 The present invention therefore also provides a pharmaceutical composition which comprises a compound of the formula (II) or a pro-drug therefor and a pharmaceutically acceptable carrier.


The composition of this invention will normally be provided in the form of a discrete unit dose such as a tablet, capsule or defined quantity of the composition in a form suitable for dissolution to provide an injectable solution. Particularly suitable forms of such compositions are those adapted for oral administration such as tablets or capsules.

20 Unit dose compositions of this invention may contain 1 to 500 mgs of active agent. Compounds of this invention wherein the 7-position side chain is other than 2-oxo-propyl or a group convertible thereto will normally be present in such compositions in a dose from 100 to 500 mgs, for example 200 to 400 mgs. Compounds of this invention wherein the 7-position side chain is 2-oxopropyl or a group convertible thereto will normally be present in such compositions in a dose from 1 to 100 mgs, more usually 2.5 to 50 mgs for example 5 to 25 mgs. The unit dose composition will normally be taken from 1 to 4 times daily so that the normal dose for a 70 kg adult human will be from about 100 to 2000 mgs for a composition containing a compound in which the 7-position substituent is other than 2-oxopropyl or a group convertible thereto and from about 4 to 100 mgs for a composition containing a compound in which the 7-position substituent is a 2-oxopropyl group or a group convertible thereto.

30 The compositions of this invention may be formulated in conventional manner. Thus oral dosage units may contain such conventional agents as fillers (diluent), lubricants, binders, disintegrants, colourants, flavourings, surface active agents, preservatives, buffering agents, and the like. Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate and the like. Suitable lubricants include stearic acid, magnesium stearate, magnesium lauryl sulphate and the like. Injectable compositions may consist essentially of a sterile, pyrogen free compound of this invention sealed into a vial optionally together with suspending and preserving agents. Such compositions may be made up for administration with sterile water or saline.

40 The compositions may be prepared by conventional methods of blending, filling, tableting or the like.

The present invention also provides a process for the preparation of the compounds of this invention which process comprises the reaction of a salt of a compound of the formula (VII):



55 wherein R<sub>1</sub>, R<sub>2</sub>, X and Y are as defined in relation to formula (II) with a compound of the formula (VIII):



wherein n and m are as defined in relation to formula (II) or a chemical equivalent thereof.

60 Suitable chemical equivalents of the chloro-compound of the formula (VIII) include the corresponding bromo- and iodo-compounds and analogous active esters such as mesylates or tosylates.

The salt of the compound of the formula (VII) will normally be an alkali metal salt such as the sodium or potassium salt and may be preformed or generated in situ by the presence of a base such as an hydroxide or ethanolate.

65

# 0018 136

Suitable solvents for use in such processes include lower alkanols such as methanol, ethanol or the like.

The reaction is generally carried out at an ambient or elevated temperature, for example from 20° to 80°C. It is often convenient to carry out the reaction in a solvent under reflux.


When the desired compound has been produced it may be recovered by distilling off the solvent, by precipitation with a miscible non-solvent or the like.

Purification of the compound of this invention may be carried out by conventional methods such as crystallisation, recrystallation and chromatography.

Compounds of the formula (II) wherein n is 2 may be prepared by the reaction of a compound of the formula (VII) with methyl vinyl ketone or 2-chlorobutan-3-one. This reaction may be carried out under conditions as described herein for reaction with a compound of the formula (VIII).

Compounds of the formula (VII) wherein Y is a sulphur atom and X is an oxygen atom may be prepared by the process by of K.R.H. Wooldrige and R. Slack, J. Chem. Soc., 1962, 1863—68.

The compounds of the formula (VII) wherein X is a sulphur atom and Y is an oxygen atom may be prepared by the reaction of a compound of the formula (IX):



(IX)

wherein R<sub>1</sub> and R<sub>2</sub> are as defined in relation to formula (II) with sodium carbonate, formamide, formic acid and sodium dithionite. This reaction is generally begun at a depressed temperature such as 3—5°C and gradually warmed until completion occurs at an elevated temperature such as 160—190°C.

The compounds of formula (IX) may be prepared according to the procedures of Bredeneck et al., Chem. Ber., 88, 1306—1312 (1955). Their conversion into compounds of the formula (VIII) as described above may be viewed in the light of Papesch et al., US—A—2615020.

Compounds of the formula (VII) wherein X and Y are both sulphur atoms may be prepared by the reaction of P<sub>4</sub>S<sub>10</sub> and a compound of the formula (VIII) wherein one of X and Y is a sulphur atom and the other is an oxygen atom or both of X and Y are oxygen atoms; see for example US—A—3135753, Chem. Zentralblatt 37—2695 (1966), Chem. Zentralblatt 27—1557 (1966) and Chem. Zentralblatt 40—0983 (1968).

The following Examples illustrate the invention.

## Example 1

1-n-Butyl-3-ethyl-7-(2-oxopropyl)-6-thioxanthine (1)

1-n-Butyl-3-ethyl-6-thioxanthine (4 g) was dissolved in dimethyl formamide (30 ml) and a small amount of potassium carbonate was added. To this mixture, 1-bromopropan-2-one (2.7 g) was added dropwise at room temperature, with stirring. The reaction was heated at about 50°C for two hours. The reaction mixture was then extracted with chloroform several times, the chloroform phase washed with 1N KOH and water, dried with sodium sulphate, filtered and the chloroform removed in vacuo to yield a red/brown oil which, on crystallisation in a mixture of ethylacetate/petroleum, gave 1-n-butyl-3-ethyl-7-(2-oxopropyl)-6-thioxanthine as a white powder.

Melting point: 173—174°C  
Yield: 1 g  
Elemental Analysis

	Calculated	Found
C	54,55	55,14
H	6,49	6,34
N	18,19	17,89
O	10,39	10,60
S	10,39	10,01

# 0018 136

## Example 2

1-n-butyl-3-ethyl-7-(3-oxobutyl)-6-thioxanthine (2)

1,3-di-n-butyl-6-thioxanthine (8,3 g), methylvinylketone (2,9 ml) and triethylamine (1 ml) were dissolved in ethanol (10 ml) and the mixture was slowly heated with stirring at 40—50°C for one hour.

5 After cooling of the clear solution, the 1,3-di-n-butyl-7-(3-oxobutyl)-6-thioxanthine precipitated in the form of yellow needles.

Melting point: 118—119°C

Yield: 8,5 g

10 Elemental Analysis

	Calculated	Found
C	58,29	58,28
15 H	7,43	7,40
N	16,00	16,12
O	9,14	9,27
20 S	9,14	8,90

The structure was confirmed by NMR spectroscopy.

Using an analogous process 1-n-butyl-3-ethyl-7-(3-oxobutyl)-6-thioxanthine (2) m.pt. 127°C, was  
25 prepared in 75% yield. The crystallisation solvent was ethanol.

Elemental Analysis					
	C %	H %	N %	O %	S %
30 Calculated	55,90	6,83	17,39	9,94	9,94
35 Found	56,08 55,95	6,91 6,92	16,91 17,03	10,23 10,35	9,87 9,85

## Example 3

40 1,3-Di-n-butyl-2-thioxanthine

Sodium carbonate (8 g) was dissolved in formamide (200 ml) and 1,3-di-n-butyl-2-thio-4-aminouracil (32 g) was added at a temperature of 3°C with stirring. The mixture was cooled over a period of 1 hour and at a temperature of 3—5°C. Formic acid (16 ml) was added dropwise. The reaction mixture was allowed to stand overnight in a refrigerator. The mixture was then heated to  
45 100°C and then sodium dithionite (5 g) was added at this temperature. To complete the reaction, the mixture was heated to 190°C for 1 hour. After cooling to room temperature with stirring, the oil solidified with crystallisation. The crude product was filtered with suction. To remove coloured by-products, the crude product was dissolved in dilute sodium hydroxide, the solution treated with charcoal and precipitated with acetic acid and the compound was recrystallised from methanol/water  
50 to give 1,3-di-n-butyl-2-thioxanthine as white powder.

Melting point: 137°C

Yield: 27,2 g

55 Elemental Analysis

	Calculated	Found
C	55,69	55,76
60 H	7,19	7,16
N	19,98	19,90
O	5,77	5,82
65 S	11,43	11,44

# 0018 136

## Example 4

### 1,3-Di-n-butyl-7-(2-oxopropyl)-2-thioxanthine (3)

1,3-Di-n-butyl-2-thioxanthine (12,6 g) was treated with sodium (1,05 g) in absolute ethanol (45 ml) to give the 1,3-di-n-butyl-2-thioxanthine sodium salt by heating under reflux for one hour. 1-Bromo-propan-n-2-one ( ml) was then added dropwise and the reaction mixture was heated under reflux for a further hour. After cooling to room temperature, the precipitated sodium bromide was filtered off and the solution was evaporated to dryness. The residue was dissolved in chloroform and treated with dilute NaOH to remove unreacted starting material. The chloroform phase was washed with water, dried, filtered and evaporated in vacuo to dryness. This residue was dissolved in methanol and treated with charcoal to remove the colour of the solution. After standing the 1,3-di-n-butyl-7-(2-oxopropyl)-2-thioxanthine precipitated as a white powder.

	Melting point:	131—132°C			
	Yield:	3,5 g			
15	Elemental Analysis		Calculated	Found	
			C	57,12	57,16
20			H	7,19	7,24
			N	16,65	16,80
			O	9,51	9,40
25			S	9,53	9,56

### 1,3-Di-n-butyl-7-(2-oxopropyl)-2,6-di-thioxanthine (4)

30	Melting point:	173°C																				
	Yield:	1,2 g																				
	crystallisation solvent:	ethanol																				
	Elemental Analysis																					
		<table><tr><th></th><th>Calculated</th><th>Found</th></tr><tr><td rowspan="2">35</td><td>C</td><td>54,52</td><td>54,64</td></tr><tr><td>H</td><td>6,86</td><td>6,81</td></tr><tr><td rowspan="3">40</td><td>N</td><td>15,89</td><td>15,93</td></tr><tr><td>O</td><td>4,54</td><td>4,74</td></tr><tr><td>S</td><td>18,19</td><td>17,87</td></tr></table>		Calculated	Found	35	C	54,52	54,64	H	6,86	6,81	40	N	15,89	15,93	O	4,54	4,74	S	18,19	17,87
	Calculated	Found																				
35	C	54,52	54,64																			
	H	6,86	6,81																			
40	N	15,89	15,93																			
	O	4,54	4,74																			
	S	18,19	17,87																			

The structure was confirmed by NMR spectroscopy.

### 1,3-Di-ethyl-7-(2-oxopropyl)-2-thioxanthine (5)

50	Melting point: Yield: crystallisation solvent: Elemental Analysis	202 °C 7,9 g $\pm$ 41,9% of the theory ethanol			
			Calculated	Found	
55			C	51,41	51,18
			H	5,75	6,02
			N	19,98	19,95
60			O	11,41	11,44
			S	11,44	11,36

The structure was confirmed by NMR spectroscopy.

## 0018 136

### Example 5

#### Composition

1,3-Di-n-butyl-7-(2-oxopropyl)-2-thioxanthine, magnesium stearate and microcrystalline cellulose may be blended together and passed through a 40 mesh sieve (UK). The resulting mixture may be  
5 tabletted on a conventional rotary machine to produce a batch of 5000 tablets of the following composition:

	1,3-Di-n-butyl-7-(2-oxopropyl)- 2-thioxanthine	10 mg
10	magnesium stearate	0.2 mg
	microcrystalline cellulose	189.8 mg

#### Pharmacology

15

#### Methodology

Cats of either sex were anaesthetized by i.p. injection of urethane/choralose (120/60 mg/kg). The  
intraduodenal (i.d.) administration of compounds was conducted by means of a plastic catheter which  
was inserted into the duodenum following midline incision at the abdominal cavity.

20

#### i) $pO_2$ -measurements

Measurement of muscle surface  $pO_2$ . The skin above the measuring site (3—4 mm in diameter)  
was removed and one multiwire-surface electrode (Eschweiler, Kiel) was placed on the gastroc-  
nemius muscle of each hindlimb. The femoral artery in one hindlimb was ligated in order to induce  
25 ischaemia. Muscle temperature was controlled by means of a thermocouple (Ellab, Copenhagen). The  
electrode current was measured every 6 to 8 s and collected for periods of 4 min (Hewlett-Packard  
programmable data logger system 3051 A). After each period, mean value and standard deviation was  
calculated.

#### 30 ii) Skeletal muscle contractility

After dissection of the skin of the calf muscles, the sciatic nerve was cut about 3 cm proximal to  
the knee. The tendon of the calf muscles was cut and connected with an isometric force transducer  
(SWEMA, SG 3). In order to maintain constant differences and a resting tension of 100 p in cats and  
25 p in rats, the hindlimb was fixed at the tibia by means of a clamp. Direct stimulation of the muscles  
35 consisted of square wave pulses of 4 msec duration at a frequency of 2 Hz and at a voltage 50 V in  
cats. In order to keep the muscles wet and at a normal temperature, the muscles were continuously  
superfused with 0.9% w/v NaCl solution (38°C). Femoral blood flow was restricted by a graded  
occlusion of the artery leading to a reduction of contractility by ca. 30%. After having reached a  
constant level of the contraction force, the appropriate vehicle (NaCl or Methocel) was injected,  
40 followed by the test substance.

45

50

55

60

65

# 0018 136

## Results

### i) pO<sub>2</sub>-measurements

Compound	dosage (mg/kg) i.d.*	n	hypoxic tissue			normoxic tissue		
			C <sub>s</sub>	$\overline{\Delta pO_2}$	E	C <sub>s</sub>	$\overline{\Delta pO_2}$	E
1	12.5	2	1	1.4	1.4	1	12.9	12.9
2	12.5	3	0.67	3.8	2.7	1	7.0	7.0
	32.0	3	0.67	4.5	3.0	1	2.0	2.0
3	0.1	4	1	6.2	6.2	0.67	8.4	5.7
	0.3	4	1	5.3	5.3	1	5.7	5.7
4	2.0	4	0.75	6.6	5.0	0.5	9.9	4.9

### ii) skeletal muscle contractility

Compound	dosage (mg/kg) i.d.*	n	average increase (%)°
1	2.0	2	+22.2
	5.0	2	+12.1
2	12.5	2	+10.4

Compound	(mg/kg) i.d.*	n	increase (%)°
3	0.3	2	+ 5.3
	0.8	3	+ 7.5
	2.0	4	+10.3
	5.0	3	+17.1
5	32.0	2	+ 9.4

n = number of animals

C<sub>s</sub> = significance coefficient = number of measuring sites with significant pO<sub>2</sub> increase per total number of measuring sites.

$\overline{\Delta pO_2}$  = mean pO<sub>2</sub> increase in experiments with significant pO<sub>2</sub> increase (Torr)

E = efficiency – index = C<sub>s</sub> ×  $\overline{\Delta pO_2}$  (Torr)

Control values : E between 0 and 1.4 Torr

\* i.d. = intraduodenal application of a suspension in Methocel (methyl cellulose)  
(%)° of initial values.


### Toxicity

No toxic effects were observed at the test dosages.



## Claims

1. A compound of the formula (II):



characterised in that

X is sulphur and Y is oxygen or sulphur;

15 R<sub>1</sub> is an alkyl group of up to 6 carbon atoms;

R<sub>2</sub> is an alkyl group of up to 6 carbon atoms; and

n is 1; or


X is oxygen and Y is sulphur;

one of R<sub>1</sub> and R<sub>2</sub> is an alkyl group of up to 6 carbon atoms and the other is an alkyl group of 2 to 3

20 carbon atoms; and

n is 1 or 2.

2. A compound according to claim 1 of the formula (IV) in solid form:




characterised in that R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1.

3. A compound according to claim 2 of formula (IV) in essentially pure form.

35 4. A compound according to claim 2 of formula (IV) for use in the treatment of peripheral vascular disease.

5. A compound according to any one of claims 2, 3 and 4 which is 1,3-di-n-butyl-7-(2-oxopropyl)-2-thioxanthine.


6. A compound according to claim 1 of the formula (V) or



50 characterised in that n is as defined in claim 1, and one of R<sub>1</sub><sup>1</sup> and R<sub>2</sub><sup>2</sup> is an alkyl group of up to 6 carbon atoms and the other is an alkyl group of 2 or 3 carbon atoms.

7. 1-n-Butyl-3-ethyl-7-(2-oxopropyl)-6-thioxanthine or 1-n-butyl-3-ethyl-7-(3-ethyl-7-(3-oxo-butyl)-6-thioxanthine.

8. A compound according to claim 1 of the formula (VI):




65 characterised in that R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1.

0018 136

9. 1,3-Di-n-butyl-7-(2-oxopropyl)-2,6-dithioxanthine.


10. A pharmaceutical composition, which composition comprises a compound according to claim 1 together with a pharmaceutically acceptable carrier.

11. A process for the preparation of a compound according to claim 1, characterised by the reaction of a salt of compound of the formula (VII):



(VII)

wherein R<sub>1</sub>, R<sub>2</sub>, X and Y are as defined in claim 1 with a compound of the formula (VIII):




(VIII)

wherein n is as defined in claim 2 or a chemical equivalent thereof, or, when n is 2 in the compound of the formula (II), with methyl vinyl ketone.

Revendications

1. Composé de formule (II):



(II)

caractérisé en ce que

X est du soufre et Y est de l'oxygène ou du soufre;

R<sub>1</sub> est un groupe alcoyle jusqu'à 6 atomes de carbone;

R<sub>2</sub> est un groupe alcoyle ayant jusqu'à 6 atomes de carbone; et


n est égal à 1; ou

X est de l'oxygène et Y est du soufre;

l'un des groupes R<sub>1</sub> et R<sub>2</sub> est un groupe alcoyle ayant jusqu'à 6 atomes de carbone et l'autre est un groupe alcoyle ayant 2 à 3 atomes de carbone; et

n est égal à 1 ou 2.

2. Composé suivant la revendication 1 de formule (IV) sous forme solide:



(IV)

caractérisé en ce que R<sub>1</sub> et R<sub>2</sub> sont tels que définis dans la revendication 1.


3. Composé suivant la revendication 2 de formule (IV) sous forme essentiellement pure.

4. Composé suivant la revendication 2 de formule (IV) destiné à être utilisé pour le traitement des affections vasculaires périphériques.

5. Composé suivant l'une quelconque des revendications 2, 3 et 4, constitué par la 1,3-di-n-butyl-7-(2-oxopropyl)-2-thioxanthine.

0018 136


6. Composé suivant la revendication 1 de formule (V):



caractérisé en ce que n est tel que défini dans la revendication 1, et l'un des groupes R<sub>1</sub><sup>1</sup> et R<sub>2</sub><sup>2</sup> est un groupe alcoyle ayant jusqu'à 6 atomes de carbone et l'autre est un groupe alcoyle ayant 2 ou 3 atomes de carbone.

15 7. 1-n-Butyl-3-éthyl-7-(2-oxopropyl)-6-thioxanthine ou 1-n-butyl-3-éthyl-7-(3-oxobutyl)-6-thioxanthine.

8. Composé suivant la revendication 1 de formule (VI):




caractérisé en ce que R<sub>1</sub> et R<sub>2</sub> sont tels que définis dans la revendication 1.

9. 1,3-Di-n-butyl-7-(2-oxopropyl)-2,6-dithioxanthine.

30 10. Composition pharmaceutique renfermant un composé suivant la revendication 1, conjointement à un véhicule ou excipient pharmaceutiquement acceptable.

11. Procédé pour la préparation d'un composé suivant la revendication 1, caractérisé par la réaction d'un sel du composé de formule (VII):




45 dans laquelle R<sub>1</sub>, R<sub>2</sub>, X et Y sont tels que définis dans la revendication 1, avec un composé de formule (VIII):



50 dans laquelle n est tel que défini dans la revendication 2 ou un équivalent chimique de celui-ci, ou bien, quand n est égal à 2 dans le composé de formule (II), avec de la méthylvinylcétone.

# Patentansprüche

1. Eine Verbindung der Formel (II):




65 dadurch gekennzeichnet, daß

# 0018 136

X Schwefel und Y Sauerstoff oder Schwefel ist;  
 $R_1$  eine Alkylgruppe mit bis zu 6 Kohlenstoffatomen ist;  
 $R_2$  eine Alkylgruppe mit bis zu 6 Kohlenstoffatomen ist; und  
 $n$  1 ist; oder

5 X Sauerstoff und Y Schwefel ist;  
 eine der Gruppen  $R_1$  und  $R_2$  eine Alkylgruppe mit bis zu 6 Kohlenstoffatomen und die andere eine Alkylgruppe mit 2 bis 3 Kohlenstoffatomen ist; und  
 $n$  1 oder 2 ist.

2. Eine Verbindung gemäß Anspruch 1 der Formel (IV) in Form eines Feststoffes:



(IV)


20 dadurch gekennzeichnet, daß  $R_1$  und  $R_2$  wie in Anspruch 1 definiert sind.

3. Eine Verbindung gemäß Anspruch 2 der Formel (IV) in im wesentlichen reiner Form.

4. Eine Verbindung gemäß Anspruch 2 der Formel (IV) zur Anwendung bei der Behandlung von kreislaufbedingten Gefäßerkrankungen.

5. Eine Verbindung gemäß irgendeinem der Ansprüche 2, 3 und 4 welche 1,3-Di-n-butyl-7-(2-oxopropyl)-2-thioxanthin ist.

6. Eine Verbindung gemäß Anspruch 1 der Formel (V):




(V)

dadurch gekennzeichnet, daß  $n$  wie in Anspruch 1 definiert ist, und eine der Gruppen  $R_1$  und  $R_2$  eine Alkylgruppe mit bis zu 6 Kohlenstoffatomen und die andere eine Alkylgruppe mit 2 bis 3 Kohlenstoffatomen ist.

40 7. 1-n-Butyl-3-äthyl-7-(2-oxopropyl)-6-thioxanthin oder 1-n-Butyl-3-äthyl-7-(3-äthyl-7-(3-oxo-butyl)-6-thioxanthin.

8. Eine Verbindung gemäß Anspruch 1 der Formel (VI)



(VI)


dadurch gekennzeichnet, daß  $R_1$  und  $R_2$  wie in Anspruch 1 definiert sind.

9. 1,3-Di-n-butyl-7-(2-oxopropyl)-2,6-dithioxanthin.


55 10. Eine pharmazeutische Zusammensetzung, welche Zusammensetzung eine Verbindung gemäß Anspruch 1 zusammen mit einem pharmazeutischen verträglichen Träger enthält.

O 18 136

11. Ein Verfahren zur Herstellung einer Verbindung gemäß Anspruch 1, gekennzeichnet durch die Umsetzung eines Salzes der Verbindung der Formel (VII):



in welcher  $R_1$ ,  $R_2$ , X und Y wie in Anspruch 1 definiert sind, mit einer Verbindung der Formel (VIII):



in welcher n wie in Anspruch 2 definiert ist, oder einem chemischen Äquivalent davon, oder, wenn n in der Verbindung der Formel (II) 2 bedeutet, mit Methylvinylketon.

20

25

30

35

40

45

50

55

60

65